← All Sight Sciences, INC filings

Sight Sciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SGHT
Sight Sciences, INC
10-K: Sight Sciences 2025 Annual Report: Glaucoma Flat, Dry Eye Down Amid Restructuring
Sight Sciences reports a net loss of $38.4 million for 2025, with flat Interventional Glaucoma revenue and a significant decline in Interventional Dry Eye sales, alongside a 20% workforce reduction.
NASDAQ
SGHT
Sight Sciences, INC
10-K: Sight Sciences Reports 2024 Results, Navigates Reimbursement Challenges
Sight Sciences' 2024 results reveal a mixed performance, with Surgical Glaucoma revenue growth offset by Dry Eye revenue decline amid reimbursement hurdles.
NASDAQ
SGHT
Sight Sciences, INC
10-K: Sight Sciences Details Capital Structure and Regulatory Landscape in 10-K Filing
Sight Sciences' 10-K filing outlines the company's capital structure, regulatory environment, and risk factors, highlighting its reliance on key products and the competitive landscape.